The elvitegravir Quad pill: The first once-daily dual-target anti-HIV tablet

Expert Opinion on Investigational Drugs

Volumn 21, Issue 7, 2012, Pages 901-904

  Marchand, Christophe ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Dolutegravir; Elvitegravir; HIV 1 integrase; Raltegravir

Indexed keywords

572 TRII PILL; ABACAVIR; ABACAVIR PLUS LAMIVUDINE; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; AMPRENAVIR; ATAZANAVIR; COBICISTAT; DARUNAVIR; DELAVIRDINE; DIDANOSINE; DOLUTEGRAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ELVITEGRAVIR; EMTRICITABINE; EMTRICITABINE PLUS RILPIVIRINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; ENFUVIRTIDE; ETRAVIRINE; FOSAMPRENAVIR; INDINAVIR; INTEGRASE; LAMIVUDINE; LAMIVUDINE PLUS ZIDOVUDINE; LOPINAVIR PLUS RITONAVIR; NELFINAVIR; NEVIRAPINE; QUAD PILL; RALTEGRAVIR; RILPIVIRINE; RITONAVIR; RNA DIRECTED DNA POLYMERASE; SAQUINAVIR; STAVUDINE; TENOFOVIR DISOPROXIL; TIPRANAVIR; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZALCITABINE; ZIDOVUDINE;

CLINICAL TRIAL (TOPIC); DRUG APPROVAL; DRUG FORMULATION; DRUG TARGETING; ENZYME INHIBITION; FOOD AND DRUG ADMINISTRATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MULTIDRUG RESISTANCE; PILL; REVIEW; TABLET;

ADENINE; ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CARBAMATES; CLINICAL TRIALS AS TOPIC; DEOXYCYTIDINE; DRUG ADMINISTRATION SCHEDULE; DRUG COMBINATIONS; HIV INFECTIONS; HUMANS; ORGANOPHOSPHONATES; QUINOLONES; TABLETS; THIAZOLES;

EID: 84862285709     PISSN: 13543784     EISSN: 17447658     Source Type: Journal    
DOI: 10.1517/13543784.2012.685653     Document Type: Review

References (16)

1. Grinsztejn B, Nguyen BY, Katlama C, et al. Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial. Lancet 2007;369(9569):1261-9 (Pubitemid 46553846)
2. Markowitz M, Nguyen BY, Gotuzzo E, et al. Sustained antiretroviral effect of raltegravir after 96 weeks of combination therapy in treatment-naive patients with HIV-1 infection. J Acquir Immune Defic Syndr 2009;52(3):350-6
3. Briz V, Leon-Leal JA, Palladino C, et al. Potent and sustained antiviral response of raltegravir-based highly active antiretroviral therapy in HIV type 1-infected children and adolescents. Pediatr Infect Dis J 2012;31(3):273-7
4. Rockstroh J, Teppler H, Zhao J, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012;13(2):127-31
5. Eron JJ Jr, Rockstroh JK, Reynes J, et al. Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase III non-inferiority trial. Lancet Infect Dis 2011;11(12):907-15
6. Marinello J, Marchand C, Mott BT, et al. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants. Biochemistry 2008;47(36):9345-54
7. Hare S, Gupta SS, Valkov E, et al. Retroviral intasome assembly and inhibition of DNA strand transfer. Nature 2010;464(7286):232-6
8. Pommier Y, Marchand C. Interfacial inhibitors: targeting macromolecular complexes. Nat Rev Drug Discov 2012;11(1):25-36
9. Metifiot M, Maddali K, Naumova A, et al. Biochemical and pharmacological analyses of HIV-1 integrase flexible loop mutants resistant to raltegravir. Biochemistry 2010;49(17):3715-22
10. Metifiot M, Vandegraaff N, Maddali K, et al. Elvitegravir overcomes resistance to raltegravir induced by integrase mutation Y143. Aids 2011;25(9):1175-8
11. Molina JM, Lamarca A, Andrade-Villanueva J, et al. Efficacy and safety of once daily elvitegravir versus twice daily raltegravir in treatment-experienced patients with HIV-1 receiving a ritonavir-boosted protease inhibitor: randomised, double-blind, phase III, non-inferiority study. Lancet Infect Dis 2012;12(1):27-35
12. van Lunzen J, Maggiolo F, Arribas JR, et al. Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase IIb trial. Lancet Infect Dis 2012;12(2):111-18
13. Johnson BC, Metifiot M, Pommier Y, et al. Molecular dynamics approaches estimate the binding energy of HIV-1 integrase inhibitors and correlate with in vitro activity. Antimicrob Agents Chemother 2012;56(1):411-19
14. Hare S, Smith SJ, Metifiot M, et al. Structural and functional analyses of the second-generation integrase strand transfer inhibitor dolutegravir (S/GSK1349572). Mol Pharmacol 2011;80(4):565-72
15. Cohen C, Elion R, Ruane P, et al. Randomized, phase II evaluation of two single-tablet regimens elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate versus efavirenz/emtricitabine/tenofovir disoproxil fumarate for the initial treatment of HIV infection. AIDS 2011;25(6):F7-12
16. Healthcare V. Shionogi-ViiV Healthcare Starts Phase III Trial for "572-Trii" Fixed-Dose Combination HIV Therapy. 2011. Available from: http://www. viivhealthcare.com/en/media-room/pressreleases/2011-02-03.aspx